

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

Sheet

1

of

1

| | |
|----------------------|--------------------|
| Application Number | 10/586,501 |
| Filing Date | September 14, 2007 |
| First Named Inventor | Martin Hendrix |
| Art Unit | 1624 |
| Examiner Name | Deepak R. Rao |

Attorney Docket Number

01-2118

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------------------|-----------------------|--|--------------------------------|--|--|
| | | Number - Kind Code ² (if known) | | | |
| Change(s) applied | A1 | 3 169 965 | 05-05-1961 | Schmidt et al. | 02/1965 |
| | A2 | 3 211 731 | 10-12-1965 | Schmidt et al. | |
| | A3 | 7 615 558 | 11-10-2009 | Hendrix | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|---|--|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | B1 | WO-2006 125548 | 11-30-2006 | Bayer Healthcare AG | | C3 |
| | B2 | CH-398 626 | 03-15-1966 | CIBA GEIGY | | A2 |
| | B3 | GB-937 723 | 09-25-1963 | CIBA LTD | | |
| | B4 | WO-2004 096811 | 11-11-2004 | PFIZER PROD INC | | |
| | B5 | WO-2004 099210 | 11-18-2004 | BAYER HEALTHCARE AG | | A3 |
| | B6 | WO-2004 099211 | 11-18-2004 | BAYER HEALTHCARE AG | | C4 |

NON PATENT LITERATURE DOCUMENTS

| | | | |
|---------------------|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C1 | WANG ET AL., "Insight into binding of phosphodiesterase-9-A selective inhibitors by crystal structures and mutagenesis," J. Med. Chem., October 12, 2009 | |
| | C2 | DENINNO ET AL., "The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents," Bioorganic & Medicinal Chemistry Letters, 2009, Vol. 9, pp. 2537-2541 | |
| | C3 | HENDRIX ET AL., "Use of Pyrazolopyrimidine Against Cardiovascular Disease," Publication Date: November 30, 2006, Data Supplied from the espacenet database Worldwide; English Abstract of WO 2006125548 | |
| | C4 | HENDRIX ET AL., "6-cyclimethyl-and 6-alkylmethyl-Substituted Pyrazolopyrimidines," Publication Date: November 18, 2004, Data Supplied from the espacenet database Worldwide; English Abstract of WO 2004099211 | |
| | C5 | WUNDER ET AL., "Characterization of the first potent and selective PDE9 inhibitor using a cGMP Reporter Cell Line," Molecular Pharmacology, 2005, Vol. 68, pp. 1775-1781 | |

Examiner Signature

/Deepak Rao/

Date Considered

10/14/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Change(s)
applied
to document,
/E.M.S./
6/16/2011

| | | | | | |
|-------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/586,501 |
| | | | | Filing Date | September 14, 2007 |
| | | | | First Named Inventor | Martin HENDRIX, et al. |
| | | | | Art Unit | 1624 |
| | | | | Examiner Name | Rao Deepak R. |
| Sheet | 1 | of | 5 | Attorney Docket Number | 01-2118 |

| U.S. PATENT DOCUMENTS | | | | | |
|---------------------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| Changes applied to document, /E.M.S./ | | 2007/0161662 A1 | 07-12-2007 | Martin HENDRIX, et al. | |
| | | 2006-0111372 A1 | 05-25-2006 | Martin HENDRIX, et al. | |
| | | 2006/0106035 A1 | 05-18-2006 | Martin HENDRIX, et al. | |
| | | 2006-0100222 A1 | 05-11-2006 | Frank-Gerhard BOSS, et al. | |
| | | 2004/0266736 A1 | 12-30-2004 | Frank WUNDER, et al. | |
| | | 2007/0105876 A1 | 05-10-2007 | Martin HENDRIX, et al. | |
| | | 5,256,668 | 10-26-1993 | Kuo HOM, et al. | Hsu et al. |
| | | 5,977,118 | 11-2-1999 | Edward R. BACON, et al. | |
| | | 5,002,949 | 3-26-1991 | Steven M. PESECKIS, et al. | |
| | | 3,732,225 | 05-08-1973 | Hermann BREUER, et al. | |
| | | 3,165,520 | 01-12-1965 | Paul SCHMIDT, et al. | |

6/16/2011
Change(s) applied to document, /E.M.S./

| FOREIGN PATENT DOCUMENTS | | | | | |
|---------------------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | |
| | | CA 2 484 997 A1 | 04-22-2003 | Bayer Cropscience AG | |
| | | CA 2 417 631 A1 | 01-29-2003 | Bayer Aktiengesellschaft | |
| | | CA 2 438 890 A1 | 09-06-2002 | Bayer Aktiengesellschaft | |
| | | CA 2 496 194 A1 | 03-04-2004 | Bayer Healthcare AG | |
| | | CA 2 496 292 A1 | 04-01-2004 | Bayer Healthcare AG | |
| | | CA 2 496 308 A1 | 04-01-2004 | Bayer Healthcare AG | |
| | | CA 2 283 211 A1 | 09-17-1998 | Bayer Aktiengesellschaft | |
| | | CH 396 923 | 01-31-1966 | CIBA Aktiengesellschaft | |
| | | CH 396 924 | 01-31-1966 | CIBA Aktiengesellschaft | |
| | | CH 396 925 | 01-31-1966 | CIBA Aktiengesellschaft | |
| | | CH 396 926 | 01-31-1966 | CIBA Aktiengesellschaft | |
| | | CH 396 927 | 01-31-1966 | CIBA Aktiengesellschaft | |
| | | DE 1 153 023 | 08-22-1963 | CIBA Aktiengesellschaft | |
| | | DE 1 149 013 | 05-22-1963 | CIBA Aktiengesellschaft | |
| | | DE 2 408 906 | 09-19-1974 | Chemische Fabrik von Heyden GmbH | |
| | | DE 1 156 415 | 10-31-1963 | CIBA Aktiengesellschaft | |
| | | DE 101 56 249 | 05-28-2003 | Bayer, AG | |
| | | DE 1 147 234 | 04-18-1963 | CIBA Aktiengesellschaft | |
| | | EP 0 995 751 A2 | 04-26-2000 | Pfizer Inc. | |
| Examiner Signature | /Deepak Rao/ | | | Date Considered | 04/11/2010 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/